Multiple Myeloma Research Foundation

Dixie-Lee Esseltine joins HBS Kraft Precision Medicine Accelerator

Friday, September 29, 2017

Dr. Dixie-Lee Esseltine, formerly the Vice President of Global Clinical Development at Takeda Pharmaceuticals, recently joined the Harvard Business School’s (HBS) Kraft Precision Medicine Accelerator. Esseltine will lead the Accelerator’s Clinical Trials work stream, which is comprised of leading nonprofit organizations (NPOs) and clinical leaders focused on precision medicine. The goal of this work stream is to accelerate the advancement of innovative platform trials across cancers by identifying best practices and sharing knowledge, helping NPOs build their understanding of the design and operation of master protocols, and working with the FDA to improve master protocols.

[Read More]

Multiple Myeloma Research Foundation to launch “Answer Fund”

Friday, August 4, 2017

The Multiple Myeloma Research Foundation (MMRF) announced that it is investing $5 million over the next three years to launch “The MMRF Answer Fund,” a multifaceted effort to address important questions facing the multiple myeloma community and to advance precision medicine. The Answer Fund will leverage the landmark MMRF CoMMpass study, which is the largest collection of genomic data of any cancer, tracking more than 1,100 myeloma patients over eight years.

[Read More]

NCI collaborates with Multiple Myeloma Research Foundation

Friday, September 30, 2016

The National Cancer Institute (NCI) has announced a collaboration with the Multiple Myeloma Research Foundation (MMRF) to incorporate MMRF’s wealth of genomic and clinical data about the disease into the NCI Genomic Data Commons (GDC), a publicly available database that promotes the sharing of genomic and clinical data among researchers and facilitates precision medicine in oncology. The MMRF, located in Norwalk, Connecticut, is the first non-profit to donate information to the GDC, which will include data on more than 30,000 patients who have many other types of cancers by the end of the year. NCI is part of the NIH.

[Read More]